<DOC>
	<DOCNO>NCT01051310</DOCNO>
	<brief_summary>The propose investigation prospective , multicenter , non-randomized study evaluate immediate benefit ( discharge 30 day ) term performance safety implantation Medtronic CoreValve PAV fail aortic bioprosthesis . In addition , study aim evaluate performance safety implantation Medtronic CoreValve PAV fail aortic bioprosthesis subsequent annual follow-up 48 month post procedure . These objective achieve follow endpoint : - Primary safety endpoint - Composite Major Adverse Events - Primary performance endpoint - Technical procedural success discharge Patient Population : Eligible subject least 75 year old , present fail aortic bioprosthesis ( stenotic , incompetent mixed ) include homograft stented stentless heterograft , consider poor surgical candidate necessitate repeat aortic valve replacement . Up 20 patient include four hospital .</brief_summary>
	<brief_title>Medtronic CoreValve REDO Study</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>&gt; 74 year old , Symptomatic fail bioprosthetic aortic valve ( stenotic , incompetent mixed ) confirm Doppler echocardiography , Logistic EuroSCORE &gt; 15 % , Any follow criterion : 1 . Left ventricular ejection fraction ( LVEF ) &lt; 20 % , 2 . Creatinine clearance &lt; 20mL/min ( estimation use Cockcroft calculation ) , 3 . Renal failure require dialysis , 4 . Permanent long lasting ( &gt; 6 month duration ) atrial fibrillation , 5 . Cirrhosis liver ( Child class A B ) , 6 . Respiratory impairment ( FEV1 &lt; 1L ) , 7 . Previous cardiac surgery ( i.e. , CABG especially patient competent mammary artery leave anterior descending ( LAD ) artery occlude saphenous vein highrisk coronary embolism reoperation ) , 8 . Pulmonary hypertension ³ 60mmHg , 9 . Recurrent pulmonary embolus , 10 . Moderate tricuspid ( &lt; grade 2+ ) insufficiency , 11 . Any severe disease contraindicate surgery , 12 . Calcified aorta ( porcelain aorta ) , 13 . Recent myocardial infarction ( le 30 day baseline ) , 14 . Contraindication cardiopulmonary bypass , Inner diameter fail bioprosthetic aortic valve ( homograft stented stentless heterograft ) ³ 19mm &lt; 26mm determine Doppler echocardiography , Signed informed consent form . Known hypersensitivity contraindication aspirin , heparin , ticlopidine clopidogrel , Nitinol , sensitivity contrast medium premedicated , Active infection endocarditis , Any intra leave ventricular mass , thrombus vegetation evidence Doppler echocardiography , Mitral tricuspid valvular insufficiency ³ grade 2+ , Prosthetic mitral tricuspid valve , Femoral and/or iliac and/or aortic vascular condition ( stenosis , occlusion tortuosity ) could complicate endovascular access aortic valve bioprosthesis , Symptomatic carotid vertebral artery narrowing ( &gt; 70 % ) disease , Aortic abdominal thoracic aneurysm , Bleeding diathesis coagulopathy , patient refuse blood transfusion , Active peptic ulcer upper gastrointestinal bleeding within past 3 month baseline , Moribund status cachexia short lifeexpectancy independent cardiac condition , Any acute neurological event dysfunction occur past 6 week baseline patient severe senile dementia , Therapeutic invasive cardiac procedure , balloon aortic valvuloplasty , perform within 30 day prior study procedure perform within 30 day study procedure , Currently , enrol study another investigational drug device study .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>